NO20050542L - Fremgangsmate for fremstilling av kalsiumsaltet fra rosuvastatin - Google Patents
Fremgangsmate for fremstilling av kalsiumsaltet fra rosuvastatinInfo
- Publication number
- NO20050542L NO20050542L NO20050542A NO20050542A NO20050542L NO 20050542 L NO20050542 L NO 20050542L NO 20050542 A NO20050542 A NO 20050542A NO 20050542 A NO20050542 A NO 20050542A NO 20050542 L NO20050542 L NO 20050542L
- Authority
- NO
- Norway
- Prior art keywords
- rosuvastatin
- preparing
- calcium salt
- calcium
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0218781.3A GB0218781D0 (en) | 2002-08-13 | 2002-08-13 | Chemical process |
PCT/GB2003/003463 WO2004014872A1 (en) | 2002-08-13 | 2003-08-07 | Process for preparing the calcium salt of rosuvastatin |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20050542L true NO20050542L (no) | 2005-02-28 |
NO329439B1 NO329439B1 (no) | 2010-10-18 |
Family
ID=9942204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20050542A NO329439B1 (no) | 2002-08-13 | 2005-01-31 | Fremgangsmate for fremstilling av kalsiumsaltet fra rosuvastatin |
Country Status (30)
Country | Link |
---|---|
US (2) | US7511140B2 (no) |
EP (1) | EP1539711B1 (no) |
JP (1) | JP4588446B2 (no) |
KR (1) | KR101325827B1 (no) |
CN (1) | CN100361979C (no) |
AR (1) | AR040868A1 (no) |
AT (1) | ATE501125T1 (no) |
AU (1) | AU2003251369B2 (no) |
BR (1) | BR0313394A (no) |
CA (1) | CA2495296C (no) |
CY (1) | CY1112412T1 (no) |
DE (1) | DE60336326D1 (no) |
DK (1) | DK1539711T3 (no) |
ES (1) | ES2361009T3 (no) |
GB (1) | GB0218781D0 (no) |
HK (1) | HK1082735A1 (no) |
IL (1) | IL166626A (no) |
IS (1) | IS7728A (no) |
MX (1) | MXPA05001582A (no) |
MY (1) | MY135301A (no) |
NO (1) | NO329439B1 (no) |
NZ (1) | NZ538070A (no) |
PL (1) | PL375296A1 (no) |
PT (1) | PT1539711E (no) |
RU (1) | RU2326871C2 (no) |
SI (1) | SI1539711T1 (no) |
TW (1) | TWI316058B (no) |
UA (1) | UA83805C2 (no) |
WO (1) | WO2004014872A1 (no) |
ZA (1) | ZA200500745B (no) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
GB0003305D0 (en) | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
GB0011120D0 (en) | 2000-05-09 | 2000-06-28 | Avecia Ltd | Process |
NL1015744C2 (nl) * | 2000-07-19 | 2002-01-22 | Dsm Nv | Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten. |
PL366831A1 (en) | 2001-07-13 | 2005-02-07 | Astrazeneca Uk Limited | Preparation of aminopyrimidine compounds |
EP1323717A1 (en) | 2001-12-27 | 2003-07-02 | Dsm N.V. | Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives |
EP1375493A1 (en) | 2002-06-17 | 2004-01-02 | Dsm N.V. | Process for the preparation of an dioxane acetic acid ester |
GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
SI1578731T1 (sl) | 2002-12-16 | 2010-02-26 | Astrazeneca Uk Ltd | Postopek za pripravo pirimidinskih spojin |
GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
WO2005023778A2 (en) * | 2003-08-28 | 2005-03-17 | Teva Pharmaceutical Industries Ltd. | Process for preparation of rosuvastatin calcium |
UY28501A1 (es) * | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
GB0321827D0 (en) * | 2003-09-18 | 2003-10-15 | Astrazeneca Uk Ltd | Chemical compounds |
GB0324791D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
TW200526596A (en) | 2003-11-24 | 2005-08-16 | Teva Pharma | Crystalline ammonium salts of rosuvastatin |
KR100887264B1 (ko) | 2003-12-02 | 2009-03-06 | 테바 파마슈티컬 인더스트리즈 리미티드 | 로수바스타틴의 특성화를 위한 기준 표준물 |
WO2005077917A1 (en) * | 2004-01-19 | 2005-08-25 | Ranbaxy Laboratories Limited | Amorphous salts of rosuvastatin |
US7241800B2 (en) | 2004-03-17 | 2007-07-10 | Mai De Ltd. | Anhydrous amorphous form of fluvastatin sodium |
US7179916B2 (en) | 2004-07-13 | 2007-02-20 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of rosuvastatin |
WO2006035277A2 (en) * | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium |
US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
US7872012B2 (en) | 2004-12-23 | 2011-01-18 | Zhejiang Hisun Pharma Co., Ltd. | Pyrimidinone compounds and preparation and use thereof |
GB0428328D0 (en) * | 2004-12-24 | 2005-02-02 | Astrazeneca Uk Ltd | Chemical process |
CA2594692A1 (en) * | 2005-01-31 | 2006-08-03 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of rosuvastatin calcium salt |
TWI353981B (en) | 2005-02-22 | 2011-12-11 | Teva Pharma | Preparation of rosuvastatin |
WO2006136407A1 (en) * | 2005-06-24 | 2006-12-28 | Lek Pharmaceuticals D.D. | Process for preparing amorphous rosuvastatin calcium free of impurities |
US8207333B2 (en) | 2005-06-24 | 2012-06-26 | Lek Pharmaceuticals D. D. | Process for preparing pure amorphous rosuvastatin calcuim |
GB0514078D0 (en) * | 2005-07-08 | 2005-08-17 | Astrazeneca Uk Ltd | Chemical process |
WO2007019373A2 (en) * | 2005-08-04 | 2007-02-15 | Transform Pharmaceuticals, Inc. | Novel formulations comprising fenofibrate and a statin, and related methods of treatment |
TW200800918A (en) | 2005-08-16 | 2008-01-01 | Teva Pharma | Rosuvastatin calcium with a low salt content |
EP1805148A2 (en) | 2005-08-16 | 2007-07-11 | Teva Pharmaceutical Industries Ltd. | Crystalline rosuvastatin intermediate |
DK1924246T3 (en) | 2005-09-15 | 2016-01-18 | Genzyme Corp | PORTION LETTER DEFINITION OF amine polymers |
US8455640B2 (en) | 2006-05-03 | 2013-06-04 | Msn Laboratories Limited | Process for statins and its pharmaceutically acceptable salts thereof |
ES2567171T3 (es) | 2006-10-09 | 2016-04-20 | Msn Laboratories Private Limited | Nuevo procedimiento para la preparación de estatinas y sus sales farmacéuticamente aceptables |
US8318933B2 (en) | 2006-10-31 | 2012-11-27 | Aurobindo Pharma Ltd | Process for preparing rosuvastatin calcium |
TW200831469A (en) * | 2006-12-01 | 2008-08-01 | Astrazeneca Uk Ltd | Chemical process |
WO2008072078A1 (en) | 2006-12-13 | 2008-06-19 | Aurobindo Pharma Limited | An improved process for preparing rosuvastatin caclium |
US8212035B2 (en) | 2007-02-08 | 2012-07-03 | Aurobindo Pharma Ltd. | Process for preparation of rosuvastatin calcium field of the invention |
WO2009009152A1 (en) * | 2007-07-12 | 2009-01-15 | Teva Pharmaceutical Industries Ltd. | Rosuvastatin intermediates and their preparation |
HU230981B1 (hu) * | 2007-10-12 | 2019-08-28 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Eljárás rosuvastatin só előállítására |
HU230637B1 (hu) * | 2007-10-12 | 2017-05-29 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Eljárás rosuvastatin intermedierek előállítására |
US8653265B2 (en) | 2008-05-27 | 2014-02-18 | Changzhou Pharmaceutical Factory | Preparation method of rosuvastatin calcium and its intermediates |
WO2010035284A2 (en) * | 2008-09-26 | 2010-04-01 | Matrix Laboratories Ltd | An improved process for the preparation of rosuvastatin calcium |
US8394956B2 (en) * | 2008-09-30 | 2013-03-12 | Aurobindo Pharma Ltd. | Process for preparing pyrimidine propenaldehyde |
CN102317267A (zh) | 2009-01-15 | 2012-01-11 | 埃吉斯药物股份公开有限公司 | 制备罗苏伐他汀盐的方法 |
US8487105B2 (en) | 2009-01-19 | 2013-07-16 | Msn Laboratories Limited | Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof |
WO2011086584A2 (en) | 2010-01-18 | 2011-07-21 | Msn Laboratories Limited | Improved process for the preparation of amide intermediates and their use thereof |
CA2796964A1 (en) | 2010-04-23 | 2011-10-27 | Ranbaxy Laboratories Limited | Intermediates for the preparation of hmg-coa reductase inhibitors |
HU230987B1 (hu) | 2010-11-29 | 2019-08-28 | Egis Gyógyszergyár Nyrt. | Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására |
CN105377817A (zh) * | 2013-03-29 | 2016-03-02 | 中化帝斯曼制药有限公司荷兰公司 | 匹伐他汀和罗素伐他汀的胺盐 |
TWM477638U (zh) * | 2013-12-12 | 2014-05-01 | 三緯國際立體列印科技股份有限公司 | 加熱平台與立體列印裝置 |
CN110198705A (zh) | 2017-01-23 | 2019-09-03 | 同和药品株式会社 | 包含hmg-coa还原酶抑制剂和氯吡格雷的复合制剂 |
MA56036A (fr) | 2019-05-27 | 2022-04-06 | Immatics Us Inc | Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive |
DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
TW202227616A (zh) | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | 分離cd8+選擇t細胞的方法 |
SI26268A (sl) | 2021-11-18 | 2023-05-31 | Zupet Rok | Postopek za pripravo hidratirane oblike perindopril l-arginina |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US663641A (en) * | 1900-10-11 | 1900-12-11 | Charles A Ruebekam | Burial-casket. |
US4645858A (en) * | 1982-03-22 | 1987-02-24 | G. D. Searle & Co. | Pentanedioic acid derivatives |
DE3741509A1 (de) * | 1987-12-08 | 1989-06-22 | Hoechst Ag | Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte |
WO1990003973A1 (en) | 1988-10-06 | 1990-04-19 | Sandoz Ag | Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them |
US5026698A (en) * | 1988-11-02 | 1991-06-25 | Nissan Chemical Industries, Ltd. | Thienopyridine type mevalonolactones |
JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
WO1993008823A1 (en) | 1991-11-06 | 1993-05-13 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
US5278313A (en) * | 1992-03-27 | 1994-01-11 | E. R. Squibb & Sons, Inc. | Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors |
ATE158579T1 (de) * | 1992-07-02 | 1997-10-15 | Hoechst Ag | Verfahren zur herstellung von (3r,5s)6-hydroxy- 3,5-0-isopropyliden-3,5-dihydroxy-hexansäure- tert.-butylester |
US5969156A (en) | 1995-07-17 | 1999-10-19 | Warner-Lambert Company | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
US6278001B1 (en) * | 1995-11-28 | 2001-08-21 | L'oréal | Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping |
FR2741620B1 (fr) | 1995-11-28 | 1997-12-26 | Oreal | Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline |
EP0907639B1 (en) | 1996-06-24 | 2003-03-12 | Novartis AG | Polymorphic compounds |
EP1055671B1 (en) * | 1998-12-10 | 2004-12-01 | Kaneka Corporation | A process for producing a simvastatin precursor |
GB9900339D0 (en) * | 1999-01-09 | 1999-02-24 | Zeneca Ltd | Chemical compounds |
GB9903472D0 (en) * | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Chemical process |
KR100649927B1 (ko) * | 1999-07-13 | 2006-11-27 | 론자 아게 | 2-아미노-4-(4-플루오르페닐)-6-알킬피리미딘-5-카르복실레이트의 제조 방법 |
WO2001022962A1 (en) | 1999-09-30 | 2001-04-05 | Merck & Co., Inc. | Anti-hypercholesterolemic drug combination |
EP1535613B1 (en) | 1999-11-17 | 2010-08-25 | Teva Pharmaceutical Industries, Ltd. | Process for preparing a polymorphic form of atorvastatin calcium |
GB0001621D0 (en) | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
GB0003305D0 (en) * | 2000-02-15 | 2000-04-05 | Zeneca Ltd | Pyrimidine derivatives |
WO2001072706A1 (en) | 2000-03-28 | 2001-10-04 | Biocon India Limited | Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
GB0011120D0 (en) * | 2000-05-09 | 2000-06-28 | Avecia Ltd | Process |
GB0011163D0 (en) * | 2000-05-10 | 2000-06-28 | Astrazeneca Ab | Chemical compound |
NL1015744C2 (nl) * | 2000-07-19 | 2002-01-22 | Dsm Nv | Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten. |
IL155194A0 (en) | 2000-10-05 | 2003-11-23 | Biogal Pharmaceutical Co Ltd | Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same |
WO2002043667A2 (en) | 2000-11-16 | 2002-06-06 | Teva Pharmaceutical Industries Ltd. | HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ -DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE |
IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
NL1017548C2 (nl) | 2001-03-09 | 2002-09-10 | Synthon Bv | Een lactonisatie proces. |
IN190564B (no) | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
MXPA03011195A (es) * | 2001-06-06 | 2004-03-18 | Bristol Myers Squibb Co | Proceso para preparacion de sulfonas de diol quirales e inhibidores de coa-reductasa del dihidroxiacido hmg. |
PL366831A1 (en) * | 2001-07-13 | 2005-02-07 | Astrazeneca Uk Limited | Preparation of aminopyrimidine compounds |
KR20040026705A (ko) * | 2001-08-16 | 2004-03-31 | 테바 파마슈티컬 인더스트리즈 리미티드 | 스타틴의 칼슘 염 형태의 제조 방법 |
AU2002324715B2 (en) | 2001-08-16 | 2009-03-12 | Teva Pharmaceutical Industries Ltd. | Processes for preparing calcium salt forms of statins |
CA2455842A1 (en) | 2001-08-22 | 2003-03-06 | Ciba Specialty Chemicals Holding Inc. | Process for the preparation of indole derivatives |
JP2005512516A (ja) | 2001-09-24 | 2005-05-12 | メルク エンド カムパニー インコーポレーテッド | スタチン薬物の組合せのスクリーニング方法および選択方法 |
EP1323717A1 (en) | 2001-12-27 | 2003-07-02 | Dsm N.V. | Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives |
KR100511533B1 (ko) | 2002-04-09 | 2005-08-31 | 임광민 | 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법 |
BR0311195A (pt) | 2002-05-21 | 2005-02-22 | Ranbaxy Lab Ltd | Processo de preparação de rosuvastatina |
EP1375493A1 (en) | 2002-06-17 | 2004-01-02 | Dsm N.V. | Process for the preparation of an dioxane acetic acid ester |
GB0218781D0 (en) * | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
DE60239428D1 (no) | 2002-12-10 | 2011-04-21 | Ranbaxy Lab Ltd | |
SI1578731T1 (sl) | 2002-12-16 | 2010-02-26 | Astrazeneca Uk Ltd | Postopek za pripravo pirimidinskih spojin |
CA2520740C (en) | 2003-04-11 | 2012-06-05 | Lek Pharmaceuticals D.D. | Process for the preparation of amorphous calcium salt of atorvastatin |
WO2004103977A2 (en) | 2003-05-21 | 2004-12-02 | Ciba Specialty Chemicals Holding Inc. | Process for the preparation of pyrimidine derivatives |
GB0312896D0 (en) * | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
AU2003247327A1 (en) | 2003-07-15 | 2005-01-28 | Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. | Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form |
WO2005023778A2 (en) | 2003-08-28 | 2005-03-17 | Teva Pharmaceutical Industries Ltd. | Process for preparation of rosuvastatin calcium |
UY28501A1 (es) | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
GB0321827D0 (en) | 2003-09-18 | 2003-10-15 | Astrazeneca Uk Ltd | Chemical compounds |
GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
EP1678148A1 (en) | 2003-10-22 | 2006-07-12 | Ranbaxy Laboratories Limited | Process for the preparation of amorphous rosuvastatin calcium |
GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
DE10352659B4 (de) | 2003-11-11 | 2007-09-13 | Ratiopharm Gmbh | Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren |
TW200526596A (en) | 2003-11-24 | 2005-08-16 | Teva Pharma | Crystalline ammonium salts of rosuvastatin |
US7028631B2 (en) * | 2003-11-24 | 2006-04-18 | The Boeing Company | Gliding submersible transport system |
WO2005077916A1 (en) | 2004-01-19 | 2005-08-25 | Ranbaxy Laboratories Limited | Salts of hmg-coa reductase inhibitors and use thereof |
KR100887264B1 (ko) | 2003-12-02 | 2009-03-06 | 테바 파마슈티컬 인더스트리즈 리미티드 | 로수바스타틴의 특성화를 위한 기준 표준물 |
WO2005054207A1 (en) * | 2003-12-04 | 2005-06-16 | Glenmark Pharmaceuticals Limited | Process for the preparation of pyrimidine derivatives |
WO2005063728A2 (en) | 2003-12-24 | 2005-07-14 | Teva Pharmaceutical Industries Ltd. | Process for preparation of statins with high syn to anti ratio |
CZ200486A3 (cs) | 2004-01-16 | 2005-08-17 | Zentiva, A.S. | Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny |
WO2005077917A1 (en) | 2004-01-19 | 2005-08-25 | Ranbaxy Laboratories Limited | Amorphous salts of rosuvastatin |
US7241800B2 (en) * | 2004-03-17 | 2007-07-10 | Mai De Ltd. | Anhydrous amorphous form of fluvastatin sodium |
GB0406757D0 (en) | 2004-03-26 | 2004-04-28 | Avecia Ltd | Process and compounds |
US7161004B2 (en) * | 2004-06-21 | 2007-01-09 | Dr. Reddy's Laboratories Limited | Processes to produce intermediates for rosuvastatin |
US7179916B2 (en) | 2004-07-13 | 2007-02-20 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of rosuvastatin |
WO2006035277A2 (en) | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium |
GB0428328D0 (en) * | 2004-12-24 | 2005-02-02 | Astrazeneca Uk Ltd | Chemical process |
CA2594692A1 (en) | 2005-01-31 | 2006-08-03 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of rosuvastatin calcium salt |
CA2498978A1 (en) | 2005-02-28 | 2006-08-28 | Apotex Pharmachem Inc. | An improved process for the preparation of atorvastatin and intermediates |
GB0514078D0 (en) * | 2005-07-08 | 2005-08-17 | Astrazeneca Uk Ltd | Chemical process |
TW200831469A (en) * | 2006-12-01 | 2008-08-01 | Astrazeneca Uk Ltd | Chemical process |
-
2002
- 2002-08-13 GB GBGB0218781.3A patent/GB0218781D0/en not_active Ceased
-
2003
- 2003-07-08 UA UAA200500711A patent/UA83805C2/uk unknown
- 2003-08-07 SI SI200331993T patent/SI1539711T1/sl unknown
- 2003-08-07 BR BR0313394-0A patent/BR0313394A/pt not_active IP Right Cessation
- 2003-08-07 ES ES03784274T patent/ES2361009T3/es not_active Expired - Lifetime
- 2003-08-07 MX MXPA05001582A patent/MXPA05001582A/es active IP Right Grant
- 2003-08-07 KR KR1020057002408A patent/KR101325827B1/ko active IP Right Grant
- 2003-08-07 CN CNB038239949A patent/CN100361979C/zh not_active Expired - Lifetime
- 2003-08-07 DK DK03784274.7T patent/DK1539711T3/da active
- 2003-08-07 JP JP2004527041A patent/JP4588446B2/ja not_active Expired - Lifetime
- 2003-08-07 PL PL03375296A patent/PL375296A1/xx unknown
- 2003-08-07 US US10/524,235 patent/US7511140B2/en not_active Expired - Lifetime
- 2003-08-07 NZ NZ538070A patent/NZ538070A/en not_active IP Right Cessation
- 2003-08-07 CA CA2495296A patent/CA2495296C/en not_active Expired - Fee Related
- 2003-08-07 PT PT03784274T patent/PT1539711E/pt unknown
- 2003-08-07 AU AU2003251369A patent/AU2003251369B2/en not_active Expired
- 2003-08-07 WO PCT/GB2003/003463 patent/WO2004014872A1/en active Application Filing
- 2003-08-07 AT AT03784274T patent/ATE501125T1/de active
- 2003-08-07 DE DE60336326T patent/DE60336326D1/de not_active Expired - Lifetime
- 2003-08-07 EP EP03784274A patent/EP1539711B1/en not_active Revoked
- 2003-08-07 RU RU2005102391/04A patent/RU2326871C2/ru active
- 2003-08-07 TW TW092121663A patent/TWI316058B/zh not_active IP Right Cessation
- 2003-08-11 MY MYPI20033048A patent/MY135301A/en unknown
- 2003-08-13 AR AR20030102929A patent/AR040868A1/es unknown
-
2005
- 2005-01-31 NO NO20050542A patent/NO329439B1/no not_active IP Right Cessation
- 2005-02-01 IL IL166626A patent/IL166626A/en unknown
- 2005-03-08 IS IS7728A patent/IS7728A/is unknown
-
2006
- 2006-01-10 ZA ZA200500745A patent/ZA200500745B/en unknown
- 2006-02-27 HK HK06102591A patent/HK1082735A1/xx not_active IP Right Cessation
-
2009
- 2009-02-13 US US12/371,359 patent/US7842807B2/en not_active Expired - Lifetime
-
2011
- 2011-05-09 CY CY20111100442T patent/CY1112412T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20050542L (no) | Fremgangsmate for fremstilling av kalsiumsaltet fra rosuvastatin | |
HUS1900052I1 (hu) | 2-acilaminotiazol-származékok vagy sóik | |
NO20041082L (no) | Fremgangsmater for fremstilling av kalsiumsaltformer av statiner | |
NO20050144D0 (no) | Fremgangsmate for a fremstille substituerte pyrimidiner | |
IL173858A0 (en) | Process for preparation of rosuvastatin calcium | |
NO20055730D0 (no) | Forbedret produksjon av rosuvastatin kalsiumsalt | |
ZA200500621B (en) | 2-cyano-4-fluoropyrrolidine derivative or its salt | |
IL216449A0 (en) | Process for the preparation of tetrazole derivatives | |
HUP0500851A3 (en) | Process for the preparation of rosuvastatin | |
NO20052568D0 (no) | Fremgangsmate for fremstilling av makrolidforbindelse | |
NO20043586L (no) | Fremgangsmate for fremstilling av organiske forbindelser | |
NO20033408D0 (no) | Fremgangsmåte for fremstilling av krystallinske nanopartikler | |
NO20044814L (no) | Fremgangsmate for fremstilling av combretastaniner | |
NO20052471D0 (no) | Fremgangsmate for fremstilling av 3-metyltiopropanal. | |
NO20041850L (no) | Fremgangsmate for dannelse av profenkrystaller | |
FR2869030B1 (fr) | Procede de production d'alpha-alumine particulaire | |
NO20044050L (no) | Fremgangsmate for syntese av chirale N-aryl-piperaziner | |
NO20034597D0 (no) | Fremgangsmåte for fremstilling av cantaxantin | |
EP1556400A4 (en) | PROCESS FOR THE PREPARATION OF 2-HALOGEN-2-DESOXYADENOSINE COMPOUNDS FROM 2-DESOXYGUANOSINE | |
NO20052392L (no) | Fremgangsmate for fremstilling av acetylenforbindelser. | |
EG24122A (en) | Process for the synthesis of 3-cyano-6-alkoxy-7-nitro-4-quinolines | |
DE60325768D1 (de) | Substituierte aralkyl verbindungen | |
ITMI20021432A0 (it) | Metodo per produrre cefalosporine | |
DE60301264D1 (de) | Amorphe citalopram salze | |
ITPD20030158A1 (it) | Macchina per la separazione dei plafoni dai corpi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |